Lenalidomide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and NICE (England), among others, recommended or restricted lenalidomide, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
PBAC (Australia) has been harder on lenalidomide than on its own caseload: it refused 4 of 8 decisive submissions here (50%), against a base rate of 24% across everything it has assessed.
The file has been open for more than a decade: 18.6 years separate the first record, 10 Oct 2007 at HAS (France), from the most recent, 29 May 2026 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 14 Mar 2022, recommended by 29 May 2026, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for lenalidomide, 2 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 68 records date from 2023 or later.
The programme is broad: 21 distinct indication wordings are recorded for lenalidomide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
11 of these 68 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess lenalidomide, on 10 Oct 2007; CONITEC (Brazil) did not open a file until 14 Mar 2022 — an unusually long tail of 14.4 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 19 years in total.
Restriction is doing real work here: 14 of 55 decisive outcomes narrowed lenalidomide to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and NICE (England) among others.
12 of the 13 agencies here assessed lenalidomide more than once, PBAC (Australia) most often at 11 entries — repeat review is the norm for this molecule rather than the exception.
lenalidomide has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for lenalidomide reads 27 recommended, 14 not recommended, 14 restricted and 3 superseded, with 10 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 29 Jan 2025 | Knoglemarvskræft | Anbefalet | source |
| PHARMAC (New Zealand) | 1 Aug 2024 | Multiple myeloma, ASCT-eligible (induction) and ASCT-ineligible, 1st line | funding application decided · decision reached | source |
| CONITEC (Brazil) | 14 Mar 2022 | Pacientes com mieloma múltiplo inelegíveis ao transplante de célulastronco hematopoiéticas. | not incorporated | source |
| NICE (England) | 9 Mar 2022 | NICE TA774 | terminated appraisal | source |
| PBAC (Australia) | 2020 | Multiple myeloma | Multiple myeloma: | The PBAC did not recommend amendments to the PBS restriction level for… | source |
63 further decisions for lenalidomide, across 13 agencies, are not shown here. They include the most recent record on file, 29 May 2026 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 41 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 68 decisions for lenalidomide from 13 agencies, 2007 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.